Key Highlights

  • Recursion Pharmaceuticals shares closed at $3.89 today, up 5.14%.
  • The stock extends a multi-week rally sparked by its expanded Partnership with Tempus AI, announced last week.
  • The extended agreement, which runs through 2029, converts up to $84 million in discretionary payments into $42 million of committed, more predictable revenue.
  • The deal also grants Tempus a non-exclusive license to Recursion's RNA foundation model TxFM for oncology use.

Expanded Tempus AI Partnership Drives the Rally

Recursion Pharmaceuticals (NASDAQ:RXRX), a Penny Stock trading under $5 per share, closed higher today, extending a multi-week rally sparked by its expanded partnership with Tempus AI, announced last week. The extended long-term licensing agreement, which runs through 2029, converts up to $84 million in discretionary payments into $42 million of committed, more predictable revenue, while also granting Tempus a non-exclusive license to Recursion's RNA foundation model TxFM for oncology use.

Deal Reinforces the Company's AI-Driven Discovery Narrative

The deal reinforces Recursion's AI-driven drug discovery narrative and has fueled a roughly 25% share price increase over the past week, even as some analysts, including one research firm maintaining a Hold rating, note the stock remains down about 9.6% year-to-date and well below longer-term fair-value estimates. Broader healthcare and Equity markets traded mixed amid rising Treasury yields, making today's company-specific gain stand out against a more challenging macro backdrop.

A TechBio Company Industrializing Drug Discovery

Recursion Pharmaceuticals is a clinical-stage "TechBio" biotechnology company headquartered in Salt Lake City, Utah, that leverages its proprietary Recursion Operating System, combining automated biology and chemistry, high-throughput data generation and machine learning, to industrialize and accelerate drug discovery. The company is advancing a differentiated pipeline of investigational medicines across oncology, rare disease, neuroscience and immunology, and has forged major strategic collaborations with pharmaceutical partners including Roche, Bayer and Takeda.